Evidence map›Paper›PMID 40884591›Full record

ArticleBioprocess and biosystems engineering2025

Process mapping and optimization study of CHO cell cultures for mAb production using Ambr

A Bordoloi, F Talebnia Rowshan

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

A BordoloiDepartment of Sustainable Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, 73019, USA.
F Talebnia RowshanDepartment of Sustainable Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, 73019, USA. f.talebnia@ou.edu.

Funding

Economic Development Administration (EDA), USA grant number #08_79_05677
6 · The paper itself

Abstract

The demand to accelerate monoclonal antibody (mAbs) process development timelines using Chinese hamster ovary (CHO) host cells to bring therapies to patients sooner is gaining momentum. The applicability of single use high-throughput (HTP) bioreactor system such as Ambr

Indexed as

Antibodies, MonoclonalBioreactorsCell Culture TechniquesAnimalsCHO CellsCricetinaeCricetulusHigh-Throughput Screening AssaysAntibodies, MonoclonalAmbr®250CHO cellsHigh-throughput bioreactorMonoclonal antibodies (mAbs)Process mappingRSM optimization

Identifiers

PMID40884591

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.